Nanologix - Neuer Stern am Diagnostikhimmel? - 500 Beiträge pro Seite

[bluesrock]

Nanologix ist im Moment dabei seine Diagnostikverfahren von der am. Gesundheitsbehörde FDA genehmigen zu lassen.
Bedeuted: Nanologix schafft in seinen Verfahren 4 bis 12 mal schnellere Ergebnise als herkömmliche Verfahren und steht kurz vor der Zulassung zu einem zigMilliardenmarkt.

Bestätigt wurden die Ergebnisse bisher durch das Texas Health Sience Center oder Battelle ( Homepage Battelle: Battelle is the world’s largest, independent research and development organization, working to advance scientific discovery and application.
We’re accelerating innovation by bringing people, science and technology together.
From Education and Laboratory Management to National Security and Energy, Environment and Material Sciences to Health and Life Sciences, we provide innovative solutions to address the world’s most pressing needs. We partner with government, industry, and communities to enhance quality of life for people everywhere.)

Jetzt kann es ganz schnell gehen und die Aktie explodiert.

Gruß
Bluesrock

[bluesrock]

Quelle Nanologix.com :

anuary 12, 2012: NanoLogix Joins WHO StopTB Partnership

NanoLogix is pleased to announce it has been accepted as a member to the World Health Organization’s Stop TB Partnership. The organization consists of nearly 1000 partner members who are a collective force that is transforming the fight against tuberculosis in more than 100 countries. They include international and technical organizations, government programs, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector. More information on NanoLogix membership in the StopTB Partnership can be found at http://www.stoptb.org/partners/partner_profile2.asp?PID=6934…
NANOLOGIX NEWS

1.10.12 NanoLogix readies FDA applications for rapid bacteria tests Read more>>

1.10.12 NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents Read more>>

[bluesrock]

Bsp.
Anthrax (nat. Verteidigung) - bisher 24 h jetzt 1h mit nanologix
Listherien (Lebensmittel) - bisher 18-24h jetzt 5h mit nanologix
MRSA ("Klinikkeim") - bisher 18-24 jetzt 6h mit nanologix

mehr Beispiele auf Naologix.com

[bluesrock]

Hi,
Schon etwas älter, aber nicht desto weniger interessant:
Quelle news-medical.net
University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep
Published on June 7, 2011 at 7:18 AM

NanoLogix (PINK SHEETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy. The 300 patient trial will study the speed and accuracy of NanoLogix technology compared to current methods in the detection and identification of Group B Streptococcus (GBS) in pregnant women. Initial BNF results on GBS from the University of Texas Health Science Center-Houston show detection and identification within two to six hours. This is eight to twenty-four times faster than conventional methods. The trial will be the second clinical trial conducted on the NanoLogix BNF technology for Group B Strep. Results from this clinical trial will accelerate the approval of the BNF kits for use in Europe, North Africa and the Middle East. ....
Kopie Ende

Interessant: " zur Beschleunigung der Zulassung der BNF Kits in Europa,Nord Afrika und dem Mitteleren Osten".

Die Erprobung lief im Juni an und sollte in den nächsten Wochen abgeschlossen sein. Genaueres weiß ich natürlich nicht. Die Ergebnisse der Houston-Studie werden voraussichtlich bald veröffentlicht.

Quelle Nanologix press releases 19.July 2011
Findings of the study, along with Group B Strep data isolated directly from patient samples will be presented at the 78th annual meeting of the Central Association of Obstetricians and Gynecologists October 26-28, 2011.

This UTHSC - Houston study published in the American Journal of Perinatology is the first of several peer-reviewed research papers on NanoLogix technology to be published between now and early 2012.
...
Kopie Ende

Mehrere Veröffentlichungen zu den Anwendungen der BNF-Technologie sind bis Frühjahr 2012 geplant. D. h. sie werden die gesamte Anwendungspalette unterstrichen mit Studien im American Journal of Periantology veröffentlichen.

Wenn es so kommt und wir erhalten parallel hierzu die Zulassung der amerikanischen und europäischen Zulassungsbehörden, wäre dies der Durchbruch für Nanologix und die Technologie!

Gruß
Bluesrock


Gruß
Bluesrock

[bluesrock]

Gestern wurde nur Kleinkram gehandelt. Wird Zeit das jetzt mal ein bischen Schwung in die Bude kommt.

[bluesrock]

Hi,
Kopie aus dem Yahoo-Board

Did this change on the co. website?
Getting ready to sell overseas?

I think before it was,
"All Products are for research use. Regarding International Orders: We do not accept them at this time."

Now it's,

"International orders require direct communication with Nanologix and are subject to a case by case business evaluation. Product will be sent with a 1-2 day delivery expectation. Quality cannot be guaranteed due to potential environmental conditions during transportation. Please click here to be alerted when NanoLogix technology is available outside of the U.S. "

Kopie ende

Step by Step gehts voran

[bluesrock]

Und jetzt mal mit Schwung Richtung 1$

[Gurkensaft]

Bacteria Detection Time Cut From Days to Minutes

NanoLogix Reveals Latest Developments In Summary of Operations and Events

HUBBARD, OH, February 9, 2012-- NanoLogix (PINK SHEETS: NNLX), an innovator in rapid diagnostics, today released a comprehensive operations summary that revealed an exponential drop in detection and diagnostic times for active-threat bacteria and amoeba. This development is projected to provide reliable detection, ease of use, and the ability to identify live active-threat bacteria and differentiate from non-threat bacteria, faster and at lower cost than other technologies.

In recent third-party tests, two of NanoLogix’s products, the BioNanoPore (BNP) and BioNanoFilter (BNF), provided diagnostic results 4 to 20 times faster than standard tests. Group B Streptococcus, a threat during pregnancy, took an hour or less rather than the standard 48-72 hours. Tuberculosis detection was reduced from weeks to 4 days.

These details are included in today’s comprehensive summary of NanoLogix business operations, which covers technology advances, partnership collaborations, preparations for FDA approvals, media coverage, financial information and the company’s new R&D laboratory.
 
To view the NanoLogix Company Summary, please visit: http://nanologix.com/news/2011_company_update.html

[bluesrock]

Hey Gurkensaft, sei gegrüßt.

Bluesrock

[Gurkensaft]

http://www.nanologix.com/test_results.html

Hier wurden nochmals die Ergebnisse aktualisiert - das sieht nun sehr ordentlich aus:

Anthrax <1hr**
Bubonic plague <1hr**
Cholera <1hr**
GSB <1hr**
MRSA 6hrs**
TB 4days**

** external third party

[bluesrock]

Quelle Nanologix.com:
February 13, 2012: Group B Strep research from University of Texas Health Science Center presented at the Society for Maternal-Fetal Medicine Annual Meeting poster session. View the poster here>>

Auszug:

RESULTS: 124 patient samples were screened, of which 33 were positive for GBS by the rapid test (97.0% concordance with traditional culture). Of these 33 positive samples, 10 were resistant to clindamycin, which agreed 100% with traditional culture. Results of the both the rapid and traditional culture showed 100% concordance with sensitivity or resistance to clindamycin when compared with commercial lab results.

Kopie ende

Nicht nur , das die Ergebnisse wesentlich schneller vorlagen als mit gebräuchlichen Verfahren. Nein sie zeigen zudem die Antibiotikaresistenz bei den getesteten Frauen.

Und 100% Übereinstimmung mit traditionellen Verfahren. Bingo

[bluesrock]

So langsam schließt sich das Fenster. Wenn die Zulassung der FDA kommt, gibts kein halten mehr.

Und daran möchte ich erinnern:

EPA AND NANOLOGIX ENTER INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR RAPID WATER QUALITY TESTING

Hubbard, OH (Marketwire – 08/23/10) - NanoLogix, Inc. (Pinksheets:NNLX - News) The U.S. Environmental Protection Agency announced it has entered into a Cooperative Research and Development Agreement (CRADA) with NanoLogix. The Agency and NanoLogix will work to design a rapid diagnostic method to detect bacterial threats, including E.coli and Cryptosporidium in drinking and source water. Scientists from the EPA and NanoLogix will use the company’s rapid detection technology as a foundation for the new process, with the goal of significantly reduced test times from those achievable with current tests.

“Working with the EPA on water quality testing is a significant milestone in our corporate development,” said NanoLogix CEO Bret Barnhizer, “It’s been a long process to achieve this multi-year CRADA and we are pleased to be able to collaborate with the EPA on improving the safety and quality of the U.S. national water supply.” More on the EPA’s announcement of the CRADA with NanoLogix can be found at: epa.gov/microbes/mceardnews.html

Kopie Ende

August 2010 - Auch hier könnte demnächst ein update kommen.

Gruß
Bluesrock

[bluesrock]

Auf gehts, brennt die Lunte an und laßt das Baby explodieren

[Gurkensaft]

Ja ... das kann nicht mehr lange dauern!

Die Frage ist nur, wann wir das FDA approval bekommen ...

Die "external third party results" werden auch immer zahlreicher - fast alle unter einer Stunde:
http://www.nanologix.com/test_results.html

[bluesrock]

Antwort auf Beitrag Nr.: 42.828.572 von Gurkensaft am 29.02.12 19:30:39

Yep und die Welt braucht dringend Antworten auf eine neue Bedrohung die da heißt Multi Resistente Keime und deren rechtzeitige Erkennung. Z. B. auf der Bremer Frühchenstation läuft einiges aus dem Ruder. Aber nicht nur dort. Geschätzte 900.000 Erkrnkungen jedes Jahr - ca. 40.000 Tote - nur in Deutschland. Die Leute müßen endlich aufwachen - sonst gibts von der Menschheit bald nur noch Restbestände. Ist kein Witz- das ist meine Meinung und ich bin im Gesundheitswesen beschäftigt - ich weiß von was ich rede den ich bekomm es Tag täglich mit.

Gruß
Bluesrock

[bluesrock]

GuutesVolumen - weiter so ich riech schon das geschmurgel an der Lunte

[Gurkensaft]

Tuberculosis liegt mit BNF nun bei 1,5 Stunden:

http://www.nanologix.com/bacteria/tb.html

[bluesrock]

Tick-Tack-Tick-Tack...

[Gurkensaft]

http://www.nanologix.com/cms-assets/documents/54717-248038.n…

59th annual scientific meeting of the Society for Gynecologic Investigation:
Erste offizielle "Bestätigung", dass GBS mit BNF in unter einer Stunde identifiziert werden kann.

Die Frage ist nun nur, wie weit wir im FDA Zulassungsverfahren nun sind ...

[bluesrock]

Hi Gurkensaft,
irgendwie unsexy zur Zeit. Da fällt mir grad aber auch gar nix possitives ein. Wenigsten funkt die Advanced Medical German Co. wieder Lebenszeichen

http://www.amgkwt.com

Bis die Tage

Bluesrock

[Gurkensaft]

Ja ... nur leider hat Nanologix die Zusammenarbeit mit Advanced Medical German Company beendet, da die sie ihren Verpflichtungen nicht nachgekommen sind ...

http://nanologix.com/news/2011_company_update.html
NanoLogix has unilaterally cancelled a letter of appointment it had with Advanced Medical German Company, a Kuwaiti company. The Kuwaiti company had financial responsibility for a planned clinical study in Europe that did not happen.

[Gurkensaft]

Guter Überblick für neue Investoren:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

[bluesrock]

Antwort auf Beitrag Nr.: 43.069.863 von Gurkensaft am 21.04.12 14:52:16

Ups,
ist mir glatt entgangen. Danke für die Info.

Gruß
Bluesrock

[bluesrock]

Gähn
Momentan keine Phantasie in der Aktie

[Gurkensaft]

NanoLogix Provides Testing and Operations Update

Dramatic Reduction In Tuberculosis (TB) Test Times, Peer-reviewed Publication for Group B Streptococcus Research

HUBBARD, OH-- April 24, 2012--A well-respected, independent, third-party laboratory has tested for Tuberculosis (TB) using NanoLogix BNP (BioNanoPore) test kits and achieved the detection of live TB colonies in 4 to 5 days.  Standard culture times for conventional technologies take a minimum of 16 to 21 days to achieve similar results.  In concurrent tests for TB at the same facility, using Nanologix BNF (BioNanoFilter) test kits, Antibody/Antigen TB-specific test results were obtained in 1 hour 30 minutes.  For research and publication purposes, all test results were confirmed with PCR.  Comprehensive results of these independent tests are currently undergoing editing for publication in a major peer-reviewed, scientific journal.

Group B Strep Research Published

Results of an ongoing (status: 340 of 350 patients complete) Group B streptococcus clinical study being conducted at the University of Texas Health Science Center - Houston, using NanoLogix technology, has been published in the April 2012 edition of the Journal of Diagnostic Microbiology and Infectious Disease. The paper is titled, Optimization of a rapid diagnostic test for detection of group B streptococcus from antepartum patients.  Authored by Dr. Jonathan Faro, et al, a full abstract of the paper can be found at  http://www.sciencedirect.com/science/article/pii/S0732889312…

NanoLogix “Flat Pack” Packaging Method Achieves Milestone With One Year Shelf Life

A major independent research facility is evaluating the shelf life of petri-based technology sealed in NanoLogix patent-pending “Flat-Pack” vacuum packaging.  The results to date demonstrate shelf life of at least one year.  The recommended shelf life for standard non-NanoLogix petri-based products packaged in standard packaging is currently three months. To read the scientific assessment, please visit http://www.nanologix.com/resources.html

New Science Advisory Board Member

NanoLogix welcomes Mark Wheeler, MD to its Science Advisory Board.  Dr. Wheeler brings an extensive medical, investment and business background to the Advisory Board.  For more information about Dr. Wheeler please visit  http://nanologix.com/about/team.html.

First and Second Quarter Business Developments

At the 2012 ASM BioDefense and Emerging Diseases Conference and the Food Safety Summit, NanoLogix received strong interest in its technology from multiple corporate and institutional entities, domestic and foreign. NanoLogix exhibited at both events, which were held in February and April, respectively, in Washington D.C.

In addition to US sales, the company has recently shipped BNP and/or BNF test kits to Europe, India, Turkey and the Middle East. 

[bluesrock]

jetzt kann es aufwärts gehen.

[bluesrock]

Hi,
letztendlich war das eine Meldung wie wir sie leider in den letzten Jahren zu häufig gehöhrt haben. Könnte alles auch heiße Luft sein, das da abgelassen wird. Und die. die nanologix kennen kratzt das nicht mehr. Jetzt muß Butter bei de Fische - und sonst gar nichts!

gruß
bluesrock

[Gurkensaft]

Ja ... da hast vollkommen recht!

Die Entwicklungen und Veröffentlichungen sind grds. gut aber wir brauchen jetzt endlich das FDA-Approval ...

[bluesrock]

Schnarch,
aber da müßen wir jetzt durch. Wenn die FDA-Genehmigung vorliegt geht s ab. Zudem wird ja noch an einem Wassertest mit der EPA geforscht.

Gugst du:
Quelle Nanologix 19.07.2011

NanoLogix Announces Expansion of EPA Work on Rapid Tests for Drinking Water Quality and Provides Update on Publication of Group B Streptococcus Trial

HUBBARD, Ohio--NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens. To accommodate the additional research, the company will add two scientists to its staff at its Cincinnati laboratory. More information on the NanoLogix CRADA can be found at the EPA MCEARD News Archive where an article on the company's work can be found two-thirds down the page.

Also, ruhig Blut, es kommt schon noch alles in Wallung

Gruß
Bluesrock

[Gurkensaft]

Sehe ich auch so! Nanologix wird seinen Weg gehen!

Allerdings könnte der Weg gerne auch ein wenig schneller beschritten werden.

Aber gut Ding braucht ja bekannter Weise Weile ...

[Gurkensaft]

http://www.nanologix.com/news/updates.html


 May 14, 2012: Data Collection Completed for Group B Strep Clinical Study
 

NanoLogix has reached a milestone with the completion of a 352-patient clinical study focused on rapid detection of Group B Streptococcus in pregnant patients.  Conducted at University of Texas Health Science Center in Houston under Jonathan Faro, PhD, MD, the study confirms dramatic improvements in detection, identification, and determination of the antibiotic sensitivity of Group B Streptococcus with results for the entire process in 6 hours or less.
 

This represents the latest phase in the evolution of NanoLogix technology within the past eighteen months. Revision of testing protocols during that time have led to results significantly faster and more specific than in initial tests done with NanoLogix products in 2010. This clinical study also marks the first time NanoLogix technology has been used with samples from human patients.  Clinical studies, as opposed to clinical trials, are limited to research without medical intervention.  NanoLogix anticipates the next step to be a clinical trial with medical intervention.
 

The results of the completed clinical study are being prepared for publication in a major peer-reviewed medical science journal. The information on results of the 352-patient sampling is being submitted to the FDA as a non-invasive diagnostic kit application, with results forwarded to both the Centers for Disease Control and the World Health Organization.
 

The University of Texas Health Science Center has recently revised its regulations for staff involvement with private companies.  In order to comply with this change, Drs. Sebastian Faro and Alan Katz have resigned from the NanoLogix Science Advisory Board. Both Dr. Faro and Dr. Katz will continue to participate in research involving NanoLogix technology. 

[Gurkensaft]

http://www.nanologix.com/news/updates.html

May 21, 2012: Updates to Cleanroom Manufacturing Operation

NanoLogix has recently completed major changes and updates to the cleanroom manufacturing operation. These enhancements have been implemented to optimize product quality and the manufacturing process. A computerized, state of the art, environmental monitoring system designed by LIGHTHOUSE Worldwide Solutions has been installed and is in operation. This system continuously monitors air quality, temperature, humidity, and air pressure on a real-time basis. Our cleanroom air filtration system has been re-designed to maximize the quality of the air within the space. The air filtration system has been upgraded to include 10 high-quality AIRGUARD filters, thus enabling our manufacturing space to operate at a solid ISO 6 level in a static mode as described within ISO 14644-1 Cleanroom Standards.

[Gurkensaft]

Pharma Magazine: Opening the QA/QC Microbe Bottleneck with Fast Advanced Culture
http://nanologix.com/cms-assets/documents/62788-588655.nnlx-…

[Danny767]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Danny767]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Gurkensaft]

Nett ...

http://healthnewstexas.com/7554/texas-health-science-center-…

[Gurkensaft]

Methods and Devices for Rapid Detection and Identification of Live Microorganisms by Aptamers and/or Antibodies Immobilized on Permeable Membranes

[Gurkensaft]

http://www.freepatentsonline.com/y2012/0129157.html

[Gurkensaft]

July 5, 2102: NanoLogix Announces Vendor Status
The company is pleased to announce it has been selected as a vender by a multi-billion dollar US research and development corporation. The corporation has notified NanoLogix it intends to use approximately 12,000 units of NanoLogix detection technology for a project beginning in July 2012. This marks the first large sale of NanoLogix technology.


http://www.nanologix.com/news/updates.ht...

[Gurkensaft]

NanoLogix Featured in USA Today Group B Streptococcus (GBS) Awareness Campaign
NanoLogix works with Group B Strep International to promote GBS Awareness and use of BNF rapid detection

Hubbard, OH --August 1, 2012-- NanoLogix (OTBB: NNLX), a biotechnology innovator in the rapid detection and identification of live-threat bacteria, is featured today in the USA Today Group B Strep (GBS) Awareness Campaign titled Your guide to Group B Strep. The campaign featured in the USA Today News Section promotes public education on the dangers of GBS in newborns and highlights the latest testing methods to help prevent the disease. Research using NanoLogix BNF technology, from the University of Texas Health Science Center in Houston (UTHSC), is featured in the campaign. While GBS culturing methods typically take 48 hours of incubation to obtain results, this research from UTHSC documents that NanoLogix technology can detect, identify and provide antibiotic sensitivity results for GBS in as little as four hours, four times faster than conventional methods.

It’s an honor to be included in this GBS awareness campaign,” said NanoLogix CEO Bret Barnhizer. “The strong readership of USA Today is a tremendous opportunity to help pregnant women understand the dangers of Group B Strep and the critical importance early testing plays in the health of their newborns. We look forward to our rapid tests supporting the protection of many newborns and mothers from this life-threatening disease, both in the US and abroad.”

According to Dr. James A. McGregor, M.D.C.M of Group B Strep International, “Untreated, Group B Streptococcus (GBS) infection is the most common germ-related killer of newborn babies. More accurate, rapid result tests for GBS can target use of antibiotic at birth with possible reduction of resistance to antibiotics and help avoid unnecessary disturbance of the healthy, protective bacteria inside mother and baby. Parents appreciate doctors keeping Group B Strep in mind to reduce possible infections before, during, and after pregnancy. Accurate rapid testing when labor starts or water breaks can help maximize protection from GBS infection for babies at birth.”

Marti Perhach, CEO/Cofounder of Group B Strep International stated, “I first contacted Nanologix about a year ago when I heard they were developing a new rapid test to detect Group B Strep. Having an accurate rapid test available is extremely important, especially as women may test negative during routine screening, but be positive during labor and delivery. Group B Strep International's mission is to promote awareness and prevention of Group B Strep disease in all babies throughout pregnancy and early infancy. As sponsors of July as International Group B Strep Awareness Month, we invited Nanologix to participate in our awareness campaign. We are so appreciative of their efforts in GBS awareness and the excellent information they have made available to the general public through USAToday.com.” For further information on Group B Strep awareness and prevention, please visit www.groupbstrepinternational.org

If Group B Strep-colonized mothers give birth before antibiotics can be administered, the bacteria can be passed to the newborn, causing life-threatening infections, such as meningitis and sepsis.  According to the CDC, about 25 percent of women test positive for Group B Strep and on average 1,200 American newborns less than a week old contract the disease.

The 7-day campaign featured on USA Today.com will run until Monday August 6th. Also included in the GBS Awareness campaign are the Centers for Disease Control and Prevention (CDC), the Keck School of Medicine at the University of Southern California, the Center for Vaccine Awareness & Research, and the Group B Strep Association.

[Gurkensaft]

Und hier der Link zur Kampagne:

http://sites.conversionplanet.com/group-b-strep-awareness/gr…

[Gurkensaft]

Aug 15, 2012: NanoLogix is pleased to announce that the company will begin commercial marketing of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first to be marketed will be the BNP sandwiched-membrane petri kit with TSA media. BNP kits with other nutrient media will be available in the near future by special order. Thereafter, NanoLogix plans to expand commercial operations to marketing its BNF technology for ultra-fast identification of specific subject microorganisms. The company plans to introduce commercial applications for commonly tested microorganisms, but will also work to develop client-specific customized test kits for particular applications.

The company will also initiate sales of TSA petri plates. Both BNP and Petri plates will be packaged in the company's proprietary vacuum Flat Packs.

In addition, the final results of both the University of Texas Health Science Center-Houston's clinical study for Group B Strep in pregnancies, and a large third-party research and development organization's Tuberculosis laboratory study have been submitted, by each respective institution, to major peer-reviewed medical journals for publication. One paper details the final results of the 356-patient Group B Streptococcus clinical study at the University of Texas Health Science Center in Houston. The other paper features data from the third-party laboratory responsible for using NanoLogix BNP test kits to achieve detection of live Tuberculosis colonies in five days compared to the 21-28 days attainable through normal culturing.

[Gurkensaft]

http://www.nanologix.com/about/financials.html

Die Finanzberichte der letzten 9 Quartale wurden auf der Homepage veröffentlicht!

[Gurkensaft]

NanoLogix Rapid Diagnostic Technologies Set to Enter Market Under FDA 510K-Exempt Status

HUBBARD, Ohio--(BUSINESS WIRE)--

NanoLogix (OTC Markets: NNLX), a biotechnology innovator in the rapid detection and identification of live-threat bacteria and microorganisms, announces it will begin commercialization of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first product to be marketed will be the Petri-based BNP detection kit utilizing TSA media. Other nutrient media will be available by special order. Recently completed independent third-party research has demonstrated BNP diagnostic kits to be two to ten times faster at live bacteria detection than traditional methods. Following the BNP rollout, NanoLogix plans to commercialize its BNF technology, which third-party research documents as 18 to 72 times faster than conventional detection and identification methods. The company also plans to develop customized test kits for particular applications and client partners.

NanoLogix is also beginning sales of conventional TSA Petri plates. Both BNP kits and NanoLogix TSA Petri plates will be packaged in the company's proprietary inert-gas charged vacuum Flat Packs. A major third-party laboratory has documented these Flat Packs to have at least a one-year shelf life stored under normal conditions, compared to the 3-month shelf life of traditional Petri plates.

Peer-Reviewed Research Pending Publication

The results of two independent third-party research studies using NanoLogix technology have been submitted by their respective organizations to major peer-reviewed medical technology journals for publication.

The first submission details the use of NanoLogix BNF test kits and final results of a 356 pregnant-patient Group B Streptococcus (GBS) clinical study at the University of Texas Health Science Center - Houston. This study attained GBS detection, identification and antibiotic-sensitivity results from samples collected in as little a 6 hours, a sharp contrast to traditional laboratory test times of 48-72 hours. One major goal in the study was to ensure the ability to test for antibiotic sensitivity in reduced time from the standard, potentially enabling physicians to rapidly tailor antibiotics to the specific infection involved and reduce the overuse of broad spectrum antibiotics. For more on GBS: http://sites.conversionplanet.com/group-b-strep-awareness/gr…

The second submission features data from a major independent laboratory documenting NanoLogix BNP test kits five-day detection of live Tuberculosis. Traditional culture delivers results in 21-28 days.

[Gurkensaft]

US Environmental Protection Agency Issues Featured News Article Covering Cooperation With Water test development highlighted.

Significant sales increase in Q3, company welcomes Giles Manley, MD to Science Advisory Board

HUBBARD, Ohio--(BUSINESS WIRE)--
NanoLogix (OTC Markets: NNLX) is the subject of a featured news article released last week by the US Environmental Protection Agency. The article covers the progress of an ongoing Cooperative Research and Development Agreement (CRADA) in place between the EPA and NanoLogix. The objective of the CRADA is to develop a comprehensive water quality test kit for use in testing drinking and source waters in the EPA’s ten regions.
The article can be accessed on the EPA’s site at the following link:

http://www.epa.gov/nerl/features/nanologix.html

NanoLogix is pleased to announce sales experienced a significant increase in Q3. Essentially all of Q3 and current sales have been, and are, directly to the US Federal government or to Corporations for use on classified US Government projects. These sales are comprised of BNP kits and filled Petri plates. Major marketing for BNP and BioNanoFilter (BNF) bacteria detection kits is pending publication of two recently completed third-party studies in peer-reviewed science Journals.

The company has had increasing interest in both its BioNanoPore (BNP) Petri-based sandwiched-membrane bacteria detection kits and also in standard filled Petri plates, both packed in NanoLogix’s proprietary extended-life packaging. The internally developed patent pending packaging enables storage of both BNP and Petri for over one year in cold storage, and for at least three months at room temperature.

NanoLogix is honored to welcome Giles Manley, MD to the NanoLogix Science Advisory Board (SAB). Dr. Manley brings a wealth of medical, legal and business knowledge to the SAB.
Dr. Manley’s acceptance statement: “I am grateful for the invitation, and very excited about being part of NanoLogix by serving on their Science Advisory Board. What NanoLogix has accomplished over the last several years is truly amazing. There is no comparable system in the world that can deliver bacterial identification as cost effectively, quickly and accurately as their BNF and BNP product line… Through my career I have formed acquaintances with the Chiefs of Obstetrics at some of the top medical institutions in our country. I will make a concerted effort to get the necessary trials started and finished at places such as Harvard, Johns Hopkins and other institutions. I am hopeful that by the end of 2013 the standard for GBS screening will include our near-15 minute test at time of labor.”

[Gurkensaft]

Vom yahoo Board:

"emailed questions to the CEO and as a favor to PDE, CEO provided the following answers.

The CEO does not read message boards, we run the company via agreements with defense contractors, universities, etc. Products are used in national security. We take our obligations seriously, but we are not only about the stock price. We do our business and take care of our obligations. Our obligation to our shareholders is to build a successful business, and the market will value the business – share price. We know what the share price is, but we don’t run the company based on the share price.

1. What plausible explanation can you give for a CEO to schedule 2 SH Meetings only to cancel (after the fact). Then explain it away as a cost factor. Shouldn't a CEO know beforehand the cost of a meeting (at least after the first one was cancelled)?

Answer: Our objective to to keep the company running, so often the company has to adjust plans – expenses – fund raising. Company did not know BioStart was going to lose it’s lease and that we needed to relocate lab – hire new scientists, furnish complete lab, etc, so unexpected costs do arise forcing the company to adjust plans. There is no inexpensive way to hold a Shareholders Meeting due to proxies, etc, and all the information that could be conveyed, was conveyed in the Company Update. If Billy hasn’t noticed most of the world was involved in a financial crisis over the past four years, and this hasn’t made it easier to run the company.

2. How could a CEO say that he expected significant revenue by years end years ago when we still don't have "significant revenue" today without any explanation.

Answer: CEO ‘NEVER’ said that, but that’s what Reporters printed. CEO’s does not get review rights for articles in the local paper. Asked for a retraction and never got anything back.

3. How could a CEO announce that once FDA Approval was obtained that many doors would open (paraphrasing) only to find out several months later that FDA Approval was not even needed(particularly disturbing)

Answer: FDA approval is needed for BNC. We knew BNP – BNF were FDA exempt. The company had other strategic reasons for the timing, to delay in stating FDA Exempt until after third party validations were complete, refinement of protocols for use were finalized, and to ensure the intellectual property was fully protected.

4. How could a CEO announce years ago that we would have full scale production any day now (we still don't) without as much as an explanation.

Answer: NEVER said “full production any day now”, only to reporter that “the machines would be ready to test any day now”. Misquote by reporter that many keep misquoting. The reporter that wrote the first couple articles is no longer with the newspaper.

5. After announcing our first significant sale, why would the CEO not explain a plan for sales or marketing to shareholders that are invested in his company?

Answer: We have very competitive markets, and a good marketing plan that we are not sharing with anyone at present. We will not reveal how many of which product are being sold. Marketing Plan: manufacture BNF - BNP – Petrie Dishes and sell them! We have had multiple major corporations approach NanoLogix regarding distribution of our products, but the company is not ready to announce the plan until the independent peer-reviewed papers are published. We will not compromise the integrity of the research so will not disclose the research & results until the people that did the work publish their results in peer-reviewed journals. Independent third party research means that, independent and NanoLogix can not directly influence reports, timing of publication, or where they are published. People don’t publish paper about technology that does not work.

If Billy thinks Bret is lying, then Bret welcomes the opportunity to set Billy straight! Billy knows the address of the company."

http://finance.yahoo.com/mbview/threadview/?&bn=2e8f6abb-718…

[Gurkensaft]

NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology

Major Third-party R&D lab achieves 5-day Tuberculosis detection, compared to weeks for standard tests

HUBBARD, Ohio--(BUSINESS WIRE)--

NanoLogix (OTC Markets: NNLX)

An independent third-party study by one of the foremost Biomedical Research centers in the U.S. has demonstrated that NanoLogix's BioNanoPore (BNP) Ultra-Fast Identification Technology enables detection of live Tuberculosis cultures in five days as opposed to two+ weeks with traditional methods.

The peer reviewed study appears in the online edition of the Journal of Microbial & Biochemical Technology.

http://www.omicsonline.org/1948-5948/pdfdownload.php?downloa…

The authors conclude: "Ideally, highly accurate diagnostic tests for TB would be simple to perform, not require specialized equipment or facilities, provide rapid results for decreased time to treatment, are readily available, and cost-effective for the end user. These qualities are especially important in developing or high-TB burdened countries where the access and ability to purchase specialized equipment is limited, and number of trained personnel is low. The results of the present study demonstrate a proof-of-principal for BNP™ Middlebrook in detecting TB compared to the Middlebrook 7H10 reference test and should be considered as an ideal candidate for future evaluation of clinical samples.”

Current rapid detection methods using PCR (molecular diagnostic) technology have a number of limitations in the fight against TB. They are unable to differentiate between live actual infection, and presence of dead bacteria in immune patients. Furthermore, PCR technology is very expensive, and needs specially trained personnel to perform testing, something not available, or even feasible, in the areas of the world most in need. Furthermore, even with PCR, the standard still requires culture positivity, which currently is a 3-4 week process. In addition, drug sensitivity is equally as important as identification, and early results using our BNF technology are extremely encouraging, taking only a few hours after bacterial identification.

Potential for the use of BNP technology is vast, said Bret T. Barnhizer, CEO of NanoLogix. “In addition to BNP’s use in detecting many other bacteria, we see this technology as potentially providing both a standalone method for determining the presence of an actual TB infection and also a complementary method that can be used with either our BioNanoFilter (BNF) technology or molecular diagnostics methods for initial TB screening. We hope that our BNP rapid culture results will make it possible to finally monitor antibiotic treatment for TB in a close-to-real-time manner that is currently unavailable to practitioners. This ability could provide major assistance in the ongoing campaign to combat the scourge of Tuberculosis. We are committed to helping wipe out this horrible disease that takes over one million lives a year. As a partner in the Stop TB Alliance, we look forward to working further with them and WHO officials in a real effort to eradicate TB.”

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit: www.nanologix.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

[Gurkensaft]

Update auf der web site:

Jan 22, 2013: NanoLogix Inc is pleased to announce that the results of the University of Texas Health Science Center - Houston (UTHSC - Houston) Clinical Study utilizing NanoLogix's BNF technology to detect and identify Group B Streptococcus in pregnant patients have been accepted for publication in a noted peer-reviewed journal. The 352-patient Clinical Study was performed from March 2011 through May 2012 at Memorial Hermann Hospital in Houston. In the study, times for detection and identification of GBS were reduced from 48-72 hours to 4-6 hours. In accordance with journal protocols and preservation of pre-release confidentiality, further details will be released upon publication.